| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的《药品注册证书》。现将相关情况公告如下： 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的相关情况 马来酸曲美布汀片用于治疗肠易激综合征和胃肠道运动功能紊乱引起的食 欲不振、恶心、呕吐、嗳气、腹胀、腹鸣、腹痛、腹泻、便秘等症状的改善。最 早于 1970 年在法国批准上市。目前有片剂、胶囊剂和干混悬剂等剂型在国内外 上市销售。 摩熵数据显示，马来酸曲美布汀片 2022 年、2023 年和 2024 年，全国总销 量分别为 27,553 万元、29,158 万元和 26,578 万元。 一、证书的主要内容 1、药 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-090 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于召开 2025 年第二次临时股东会的通知 （1）现场会议时间：2025 年 12 月 30 日 14:30 （1）截止 2025 年 12 月 19 日下午收市时在中国结算深圳分公司登记在册 的公司全体股东均有权出席本次股东会，也可以以书面形式委托代理人出席会 议和参加表决，该股东代理人不必是本公司股东； 一、召开会议的基本情况 （2）公司董事、监事、董事会秘书及其他相关高级管理人员； 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 （2）网络 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖南九典制药股份有限公司（以下简称"公司"）第四届董事会第十六次会 议于 2025 年 12 月 11 日在公司 921 会议室以现场结合通讯会议的方式召开，会 议通知已于 2025 年 12 月 8 日以邮件方式送达。本次会议应出席的董事 7 人， 实际出席的董事 7 人（其中以通讯方式出席会议的董事有：阳秋林女士、周从 山先生、向静女士），全体监事、高级管理人员及保荐代表人列席了会议，会议 由董事长朱志宏先生召集并主持。本次会议的召开符合有关法律、法规和《公 司章程》的规定，形成的决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于变更经营范围及修订<公司章程>的议案》； 经审议，董事会认为：议案内容符合《公司法》等相关法律法规的规 ...

九典制药公告称，公司第四届董事会第十六次会议审议多项议案。同意在经营范围中增加"信息技术咨 询服务"及"软件开发"，修订《公司章程》，提交股东会审议。逐项通过制定及修订部分治理制度的议 案，多数需提交股东会。因原审计委员会委员朱志云辞任，补选职工代表董事卢尚担任审计委员会委 员。同意与苏州缘聚医药科技签署《专利及技术转让协议》，转让费用不超4亿元。此外，将于12月30 日召开2025年第二次临时股东会。 ...

Core Viewpoint - The company indicates that the recent centralized procurement requires national medical institutions to prioritize the use of selected products, which will impact the company's revenue and profit performance in the short term due to adjustments in profit margins for its mature product, Loxoprofen Sodium Gel Patch [2] Group 1 - The centralized procurement mandates that medical institutions ensure the completion of agreed procurement volumes for selected products [2] - Loxoprofen Sodium Gel Patch is identified as a mature product of the company [2] - The current procurement pricing mechanism is expected to lead to a phase adjustment in profit margins [2]

证券日报网12月10日讯九典制药在回答调研者提问时表示，在品牌建设方面，公司采取了一系列系统而 创新的应对措施，旨在提升品牌影响力和市场认知度。公司在巩固院内市场的同时，大力拓展零售药 店、线上平台等院外市场，推动品牌向消费端深入渗透。其中，品牌升级是核心举措之一：如在2025年 12月6日，公司召开品牌升级发布会，联合国内顶尖的品牌营销咨询机构，推出"九典镇痛先生"超级符 号，强化"镇痛贴剂专家"的品牌定位，明确"贴膏药，换九典"品牌口号，直击消费者使用痛点，传递专 业、可信的品牌认知，亮相全线产品新包装，进一步增强了品牌视觉的沟通力与市场竞争力。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网12月10日讯九典制药在回答调研者提问时表示，公司四季度整体经营状况保持正常运转，市 场需求相对稳定，销售工作按计划有序进行。 ...

Group 1: Company Overview and Market Performance - The company, Hunan Jiutian Pharmaceutical Co., Ltd., reported stable operations in Q4 2025, with sales activities proceeding as planned [2] - The pharmaceutical manufacturing industry saw a revenue of CNY 12,275.2 billion in the first half of 2025, a year-on-year decrease of 1.2%, and a profit total of CNY 1,766.9 billion, down 2.8% [2] - The transdermal patch market is projected to exceed CNY 7 billion in sales in 2024, with a year-on-year growth of approximately 10%, and over CNY 4 billion in the first half of 2025, reflecting a 15% increase [3] Group 2: Product Development and Competitive Landscape - The external pain relief market is expanding due to increasing health demands and an aging population, presenting significant growth opportunities [4] - The company emphasizes R&D as a driving force, leveraging its technological expertise in gel patches to enhance product quality and brand influence [4] - The company has developed a clear and competitive external product matrix, including unique products like Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, which have significant market advantages [9] Group 3: Brand Strategy and Market Penetration - The company is implementing innovative brand strategies to enhance market recognition, including a brand upgrade event on December 6, 2025, introducing the "Jiutian Pain Relief Expert" branding [5] - The brand slogan "Pain Relief Patch, Choose Jiutian" aims to address consumer pain points and strengthen brand credibility [5] Group 4: Financial Implications and Strategic Acquisitions - The centralized procurement of Loxoprofen Sodium Gel Patch may lead to a temporary adjustment in profit margins, impacting short-term revenue and profit performance [6][7] - The acquisition of 67 drug approvals through the subsidiary Nona Pharmaceutical aims to stabilize sales and fill potential gaps caused by procurement changes [8] Group 5: Innovation and Future Directions - The company is transitioning towards innovative drug development, establishing R&D centers in central and Yangtze River Delta regions to leverage clinical resources and cost advantages [10][11] - The focus is on various cancer and chronic disease treatments, utilizing multiple drug forms and collaborative research models to enhance core competitiveness in the innovative drug sector [11]

证券日报网讯 12月9日晚间，九典制药发布公告称，公司于近日收到国家药品监督管理局签发的《药物 临床试验批准通知书》，在完成相关准备工作后将开展临床试验研究。药品名称为JMHT06。 （文章来源：证券日报） ...

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]